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Summary
Context Insulin-binding antibodies may produce severe dysglycaemia
in insulin-na€ıve patients (‘insulin autoimmune syndrome’ (IAS) or
Hirata disease), while rendering routine insulin assays unreliable.
Objective To assess the performance of clinically used insulin
assays and an optimal analytical approach in the context of IAS.
Design Observational biochemical study of selected patients
with hyperinsulinaemic hypoglycaemia.
Patients Three patients without diabetes with recurrent spontaneous
hyperinsulinaemic hypoglycaemia and ‘positive’ insulin antibodies.
Measurements A panel of clinically used insulin assays (Sie-
mens ADVIA Centaur, Siemens Immulite 2000, DiaSorin
LIAISON XL, PE AutoDELFIA and the Beckman Coulter
Access 2) were used before and after plasma dilution or poly-
ethylene glycol (PEG) precipitation. Anti-insulin IgG antibodies
were measured by IsletestTM-IAA ELISA. Gel filtration chro-
matography (GFC) was undertaken with and without preincuba-
tion of plasma with exogenous insulin.
Results Dilution of IAS plasma with assay-specific buffer
increased insulin recovery, supporting negative immunoassay
interference by antibodies. PEG precipitation of IAS plasma
decreased insulin recovery using all assays except the Immulite
2000. GFC discriminated high molecular weight and monomeric
insulin, while ex vivo addition of exogenous insulin to plasma
increased insulin bound to antibody, thereby improving the
sensitivity of detection of insulin immunocomplexes.
Conclusions Immunoprecipitation with PEG must be used
with caution in screening for insulin–antibody complexes as
results are assay dependent. GFC with addition of exogenous
insulin can identify significant insulin immunocomplexes with
enhanced sensitivity, with attendant greater clinical utility and
avoidance of radiolabelled reagents.
(Received 1 July 2016; finally revised 23 August 2016; accepted 24
August 2016)
Introduction
The existence of hormone–immunoglobulin complexes (so
called ‘macrohormones’) is well known. Such complexes pose a
significant challenge to the measurement of hormones by
immunoassay and may also interfere with bioactivity of the hor-
mones sufficiently to cause clinical disorders. Macroprolactin is
the best characterized macrohormone.1 However, macrocom-
plexes have also been described for many other hormones
including luteinising hormone,2 follicular-stimulating hormone,3
thyroid-stimulating hormone,4 human chorionic gonadotrophin5
and also insulin6. As a result of insulin having a short plasma
half-life, and because either excess insulin action or deficient
insulin action may lead to dysglycaemia and death, over minutes
and hours, respectively, anti-insulin antibodies are potentially
particularly hazardous to health.
Demonstration of insulin-binding immunoglobulin was first
reported in the circulation of patients treated with exogenous
insulin in 1955,7 and such antibodies were the focus of many stud-
ies when animal-derived insulins were commonly used. Some such
insulin-binding antibodies in plasma have been shown to alter
insulin pharmacokinetics and/or pharmacodynamics, both in
patients na€ıve to insulin therapy (‘insulin autoimmune syndrome’
(IAS) or ‘Hirata disease’)8 and in patients with labile diabetes trea-
ted with modern genetically engineered insulin analogues.9 In
both situations, patients may present with insulin resistance and/
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or hypoglycaemia, as the antibody serves both to bind and seques-
ter acutely released/administered insulin, and as a source of long-
acting bioavailable insulin as insulin dissociates from complexes
in the fasting state.10
Anti-insulin antibody assays are now widely available com-
mercially, and positive results are returned in a significant num-
ber of patients treated with insulin, and in some insulin-na€ıve
control subjects.11 These assays thus have low specificity for
detection of patients with antibodies that derange insulin kinet-
ics to a clinically significant degree. Several adjunctive
approaches have consequently been used in the assessment of
anti-insulin antibodies, most commonly including immunopre-
cipitation with polyethylene glycol (PEG), a common tool in the
evaluation of ‘macro-analytes’.12 Nevertheless, formal assessment
of this technique in tandem with modern clinical insulin
immunoassays has not been published, which is important as
PEG immunoprecipitation may compromise performance of
some immunoassays.
Gel filtration chromatography (GFC) is often cited as the gold
standard method for detecting macro-analyte complexes and has
been used to demonstrate the presence of high molecular weight
(HMW) insulin immunoreactivity in patients with dysgly-
caemia.13 However, GFC-based approaches are limited by the
dilution of the sample that occurs during filtration, meaning that
the analyte must be present at sufficiently high concentration to
be above the assay detection limit postfiltration. A further concern
is that dilution may disturb the equilibrium established between
free and bound hormone present in vivo. Detection of macro-ana-
lyte complexes may also be confounded by the so called ‘hetero-
philic’ antibody interference, caused by endogenous antibodies
that cross-react with the immunoassay components rather than
the analyte in question; both false-negative and false-positive
interferences are possible because assay components can be either
blocked or cross-linked in the absence of analyte.14,15 Both types
of interferences are assay dependent, so method comparison stud-
ies alone may neither detect nor distinguish between them. While
the distinction between macro-analyte and heterophilic antibody
interference may appear semantic, it is important for clinical deci-
sion-making, particularly in the case of insulin analysis, where
macrohormone complexes may affect insulin kinetics in vivo and
cause life-threatening metabolic complications, whereas
heterophile interference is purely an analytical challenge.
In this report, the performance of different commercially avail-
able insulin assays in the context of dilution and PEG precipita-
tion studies is assessed, and a protocol for detecting macroinsulin
complexes using GFC, with incorporation of ex vivo assessment of
increase/exchangeability of insulin binding to improve sensitivity,
is described.
Materials and methods
Patients studied and sample collection
Three patients without diabetes were evaluated by the UK Severe Insu-
lin Resistance Supraregional Assay Service, Addenbrooke’s Hospital,
Cambridge. Blood samples were collected on wet ice, and plasma/
serum were rapidly separated and frozen at80 °C until analysis. Sur-
plus plasma from patient 1 was used for the assay comparison study.
All experimental procedures were performed in accordance with the
World Medical Association Declaration of Helsinki (2000).
Anti-insulin antibody measurement
Serum anti-insulin IgG was measured using the Biomerica Isle-
testTM-IAA ELISA (Biomerica, Irvine, CA, USA) semi-quantita-
tive method.
Insulin immunoassays
Insulin was measured in pooled plasma from patient 1 using a
panel of commercially available platforms, namely Siemens
ADVIA Centaur (Siemens Healthcare Diagnostics, Camberley,
Surrey, UK), Siemens Immulite 2000 (Siemens Healthcare
Diagnostics), DiaSorin LIAISON XL (DiaSorin, Dartford, Kent,
UK), PerkinElmer AutoDELFIA (Wallac Oy, Turku, Finland)
and the Beckman Coulter Access 2 (Beckman Coulter, High
Wycombe, Buckinghamshire, UK). Insulin analysis was per-
formed in singleton, based on known assay performance charac-
teristics and in line with routine diagnostic laboratory practice.
Venous plasma insulin (LIAISON XL), C-peptide (LIAISON
XL) and glucose (Siemens ADVIA 2400 Chemistry System)
were also measured in nonfasting plasma for all three patients.
Dilution studies
Insulin was measured in neat plasma and then following a 1:4
dilution with assay-specific diluent, with starting insulin concen-
trations calculated using the dilution factor where required. Sur-
plus pooled anti-insulin antibody-negative plasma from
exogenous insulin-na€ıve patients was used as a control.
Immunoprecipitation with polyethylene glycol
The same sample from patient 1 analysed in the dilution studies
above was used. A 25% w/v solution of BDH Prolabo PEG
6000 (VWR International, Lutterworth, Leicestershire, UK) was
prepared using deionized water; 09% saline was prepared using
BDH Prolabo 18% w/v sodium chloride solution (VWR Inter-
national) and deionized water. The pooled sample from patient
1 was diluted 1:1 with 25% w/v PEG and mixed for 10 s using
a vortex and then centrifuged at 13 200 g for 15 min. Insulin
concentration was measured in the neat supernatant using the
panel of insulin immunoassays. To overcome sampling error
with the LIAISON XL (likely exacerbated by the increased
sample viscosity due to PEG), a 1:1 dilution of the PEG super-
natant was also analysed for insulin. Control plasma was as
above.
Insulin recovery was then determined in the same way for all
the three patients in nonfasting plasma and ten control samples.
Analysis was performed using the LIAISON XL, because it
demonstrates specificity for human insulin16 and has the
convenience of random access analysis.
© 2016 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
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Gel filtration chromatography
Five hundred microlitres of plasma was loaded onto a HiLoad
16/60 Superdex 75 (120 ml) size-exclusion column in combina-
tion with a 25 mmol/l Tris/052 mol/l NaCl buffer mobile phase
at pH 74, with a flow rate of 1 ml/min. Optimization studies
demonstrated that the addition of bovine serum albumin (BSA) to
fraction collector tubes before GFC improved insulin recovery
from the column, achieving >70%. Six millilitre elution volume
fractions with 1 ml bovine serum albumin (BSA) (final volume
7 ml, calculated BSA concentration 40 g/l) were collected in
Cellstar polypropylene tubes (Greiner Bio-One, Stonehouse,
Gloucestershire, UK). A total of 36–114 ml eluted volume was col-
lected.
GFC was performed using the €AKTAprime plusTM liquid chro-
matography system (GE Healthcare, Uppsala, Sweden), and
ultraviolet (UV) absorbance at 280 nm was recorded. The chro-
matography method demonstrated good precision with elution
volume coefficient of variation of 6% for immunoglobulin
(n = 30; mean elution volume 49 ml).
Samples were analysed for insulin using the LIAISON XL
immunoassay. This assay was chosen because in-house data sup-
ported high analytical sensitivity (12 pmol/l) and acceptable
coefficient of variation at lower insulin concentrations (86% at
34 pmol/l; n = 244).
Insulin exchange studies
A total of 990 ll of neat plasma was mixed with 10 ll of insu-
lin/insulin analogue of the desired concentration. The samples
were incubated on a rotator at 21 °C for 24 h before being run
through the GFC protocol described above in parallel with
samples before exogenous insulin addition.
Results
The three patients studied were female, presented with recurrent spon-
taneous hyperinsulinaemic hypoglycaemia (glucose level below
25 mmol/l confirmed on laboratory evaluation of venous blood),
‘positive’ insulin antibodies and were not treated for diabetes mellitus
at the time of blood sampling. Nonfasting samples were analysed for
insulin, C-peptide and glucose (Table 1). All the three patients had
detectable plasma C-peptide and a high insulin:C-peptide ratio17 at
times of euglycaemia. Subsequent investigation aimed to establish
whether these antibodies explained the presenting metabolic disorder.
Dilution studies
To assess insulin assay linearity in a plasma sample with insulin-
binding antibodies, dilution of the pooled heparinised plasma
from patient 1 was undertaken. As the purpose of this experi-
ment was to observe the effects of dilution on native plasma, a
sample was chosen with an insulin concentration predetermined
to be within the dynamic range of the insulin assays used. This
removed the requirement to predilute the sample, which could
affect the insulin–immunoglobulin binding equilibrium, or cause
an assay-dependent matrix effect. Pooled samples from patients
without measurable insulin antibodies were used as a control.
Five different diagnostic immunoassays were studied. Agreement
among insulin assays was consistent with known method
bias.18,19 Samples were then reanalysed following a 1:4 dilution
with assay-specific diluent. All assays showed linear insulin
recovery in the control sample (Fig. 1a); however, there was
increased recovery of insulin (Mann–Whitney test P < 005)
using all five assays in the IAS plasma following dilution
(Fig. 1b).
Immunoprecipitation with polyethylene glycol
To identify whether PEG can be used to screen for the presence
of insulin-binding antibodies using the different insulin assays,
insulin recovery in supernatant following PEG precipitation of
plasma was then studied. The same neat plasma samples anal-
ysed in the dilution studies above were diluted 1:1 with 25% w/
v PEG and, following centrifugation, insulin was measured in
the supernatant. Insulin determinations using three of the five
assay platforms of the control sample demonstrated the expected
50% dilutional effect with PEG. The exceptions were the
Immulite 2000 assay, which demonstrated paradoxically
increased insulin immunoreactivity following dilution with PEG
(Fig. 2a), and the LIAISON XL assay, which repeatedly
reported a sample error. To reduce the viscosity of the super-
natant, a 1:1 dilution with assay-specific diluent was performed.
Linearity was demonstrated in four of the five assays with
respect to neat plasma, including the LIAISON XL assay. The
Immulite 2000 still yielded a higher calculated result than mea-
sured in neat plasma, although the over-recovery was less than
seen for the 1:1 PEG diluted sample. Subsequently, a lower refer-
ence limit of 102% was defined for the LIAISON XL assay by
studying 10 further control plasma samples (median 107%; 95%
confidence interval 102–112%).
Table 1. Demographic characteristics and initial biochemical profile of patients studied
Patient
number Sex Age (years)
Nonfasting plasma
glucose (mmol/l) Insulin (pmol/l)
Insulin recovery following
PEG precipitation (%)
C-peptide
(pmol/l) Prior clinical diagnoses
1 Female 56 43 7020 8 3297 Autoimmune hypothyroidism
2 Female 28 77 1650 63 3240 Autoimmune hypothyroidism;
alcoholic hepatic cirrhosis;
systemic lupus erythematosus
3 Female 37 80 69 000 4 4960 Antiphospholipid syndrome
© 2016 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
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Using plasma from patient 1, three of the five assays demon-
strated lower insulin recoveries in PEG supernatant; however, the
Immulite 2000 assay, as before, demonstrated an increased insu-
lin immunoreactivity following dilution with PEG (Fig. 2b) and
the LIAISON XL, as before, reported a sample error. Further
assay of 1:1 diluted PEG supernatant using the ADVIA Centaur,
AutoDELFIA and the Coulter Access 2 (which had recorded
results in the supernatant) demonstrated linearity with respect to
the PEG supernatant itself, but not to the neat plasma. The
Immulite 2000 assay yielded a much lower calculated insulin con-
centration than expected in the 1:1 diluted PEG supernatant when
compared to the PEG supernatant. The calculated concentration
in the diluted PEG supernatant corresponded exactly to the value
measured in the neat plasma; however, the studies above in the
control plasma demonstrate that this is likely to be coincidental
and potentially misleading in a clinical diagnostic context, given
the over-recovery of insulin in this assay in the presence of PEG.
GFC with insulin exchange studies
Analysis was extended to the use of GFC to seek direct evidence
for the presence of macroinsulin complexes. In a control sample
with a measured plasma insulin concentration of 14pmol/l, no
insulin peaks could be seen in the eluate (Fig. 3a); this is
expected due to the dilution incurred during filtration resulting
in insulin concentrations in the eluted fractions beyond the
lower limit of the insulin assay. When the sample was preincu-
bated with exogenous human insulin to increase the measured
insulin concentration to 7655 pmol/l, the exogenous insulin was
eluted in fractions consistent with the monomeric insulin. The
combination of GFC with insulin preincubation was then tested
on the plasma from the three patients.
Fig. 1 Effect of plasma dilution and anti-insulin antibodies on insulin
determination by a panel of insulin immunoassays. Calculated insulin
concentration plotted against plasma dilution for antibody-negative
control plasma (a) and IAS plasma from patient 1 (b). Insulin
measurements were made using a panel of assays (Siemens ADVIA
Centaur, Siemens Immulite 2000, DiaSorin LIAISON XL, PE
AutoDELFIA and the Beckman Coulter Access 2) as indicated. Neat
control plasma concentrations and corresponding calculated starting
concentrations derived from assay of diluted samples were compared
using the Mann–Whitney U-test.
Fig. 2 Effect of PEG precipitation and anti-insulin antibodies on insulin
determination by a panel of insulin immunoassays. Calculated insulin
concentration in neat plasma, PEG supernatant and PEG supernatant
following 1:1 dilution in assay buffer for antibody-negative control
plasma (a) and IAS plasma from patient 1 (b) is shown. Insulin
measurements were made using a panel of assays (Siemens ADVIA
Centaur, Siemens Immulite 2000, DiaSorin LIAISON XL, PE
AutoDELFIA and the Beckman Coulter Access 2) as indicated. The
LIAISON XL analysed was unable to analyse the PEG supernatant and
reported a sample error (#).
© 2016 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
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A nonfasting sample from patient 1 with an estimated insulin
concentration of 7480 pmol/l showed peaks of immunoreactivity
consistent with both monomeric and a HMW species (macroin-
sulin). A fasting sample with an estimated insulin level of only
774 pmol/l in neat plasma from patient 1 was next used, to
challenge the discriminatory power of GFC at lower insulin con-
centrations. Despite the lower insulin concentration, a macroin-
sulin peak was still discernible (Fig. 3b). The same sample was
then preincubated, as before, with exogenous insulin, increasing
measured insulin concentration to 7840 pmol/l. The macroin-
sulin peak was greatly accentuated, consistent with an excess
insulin-binding capacity by the insulin-binding antibody. The
exogenous insulin addition not only increases the sensitivity of
the GFC method for detecting insulin-binding antibodies, but
also demonstrates that the insulin-binding complex is in
dynamic equilibrium with free insulin.
Undiluted plasma from patient 2, with an insulin concentra-
tion of 198 pmol/l, failed to demonstrate a macroinsulin peak
following GFC (Fig. 3c). Moreover, incubation with human
insulin to increase the measured concentration to 8720 pmol/l,
although enormously increasing the monomeric insulin peak,
failed to unmask any HMW insulin peak. This result is consis-
tent with the immunoassay-detected antibody not having suffi-
cient concentration and/or affinity to form demonstrable insulin
complexes ex vivo using this method. It is therefore unlikely that
significant reservoirs of bound insulin will accumulate in vivo,
so any clinical sequelae associated with the positive anti-insulin
antibody are unlikely.
Patient 3 posed a different challenge, with a plasma insulin
concentration recorded as 69 000 pmol/l. GFC of neat plasma
demonstrated a predominance of HMW, rather than mono-
meric, insulin immunoreactivity (Fig. 3d). This would be consis-
tent with the presence of an antibody with very high insulin-
binding capacity; however, the presence of heterophilic antibody
interference is an alternative explanation. As heterophilic anti-
bodies bind immunoassay reagents rather than insulin per se, a
demonstration of insulin exchange into the HMW fraction
would exclude heterophile interference. Thus, rather than
attempting to increase the HMW insulin fraction further with
exogenous human insulin, we aimed to demonstrate exchange-
ability by assessing the ability of exogenous analogue insulin to
exchange into the macroinsulin fraction. Insulin aspart was cho-
sen as it has been previously demonstrated to show low cross-
reactivity with the LIAISON XL assay.16 Analysing GFC frac-
tions using the LIAISON XL assay showed an expected
decrease in the macroinsulin fraction consistent with displace-
ment of native insulin by aspart. The monomeric insulin frac-
tion increased due to the displaced native insulin and due to the
(low) cross-reactivity with large amounts of unbound insulin
aspart. Subsequent analysis of GFC fractions with and without
insulin aspart using an assay with higher cross-reactivity with
insulin aspart16 confirmed native insulin could be displaced
from the macroinsulin complex using insulin aspart binding by
antibody (See Fig. S1).
Discussion
Immunocomplexing of hormones by endogenous antibodies to
produce so called ‘macrohormones’ can lead to apparent eleva-
tion, sometimes dramatic, of measured blood concentrations,
Fig. 3 Demonstration of reversible insulin binding to immunocomplexes using gel filtration chromatography of plasma. Results of insulin assay after
gel filtration chromatography of insulin antibody-negative control plasma or patient plasma are shown: (a) insulin antibody-negative control plasma
pre- and posthuman insulin spike, (b) patient 1 nonfasting plasma or fasting plasma pre- and posthuman insulin spike; (c) patient 2 nonfasting plasma
pre- and posthuman insulin spike; (d) patient 3 nonfasting plasma pre- and postinsulin aspart spike. Elution volumes of immunoglobulin (A), albumin
(B) and monomeric insulin (C) are shown. Insulin concentrations were measured using the DiaSorin LIAISON XL.
© 2016 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
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but usually without the expected physiological responses as the
hormone:immunoglobulin complexes are presumed to be bio-
logically inactive. Detection of such complexes can explain aber-
rant endocrine results and has great diagnostic utility.1,20,21
Unlike most macrohormone complexes which appear biologi-
cally inactive, autoantibodies with the ability to accumulate
insulin in vivo pose a major physiological risk as well as an ana-
lytical challenge: insulin autoantibodies may not only attenuate
the acute hypoglycaemic action of insulin through sequestration
of free insulin, but also commonly cause postabsorptive hypo-
glycaemia as insulin dissociates from the complex at physiologi-
cally inappropriate times. To have these effects, insulin
autoantibodies must have relatively high concentration and an
affinity that allows for insulin dissociation within a physiologi-
cally relevant time-scale. Simply detecting the presence of the
antibodies by immunoassay is not informative on these critical
points. This motivated us to explore in further detail laboratory
methods for identifying clinically significant insulin autoantibod-
ies in the context of widely available immunoassays.
In the presence of anti-insulin antibodies, the insulin concen-
tration determined by immunoassay of plasma will not neces-
sarily reflect either the total insulin (antibody-bound plus free)
or free insulin, as the equilibrium between bound and free
insulin may be affected by diluting the sample in assay buffer.
This is likely to be assay dependent as different buffers, dilu-
tions and capture antibodies may be used, and it underlies the
need for more detailed biochemical assessment in such cases.
Nonlinear immunoassay results with dilution of plasma, caused
by dissociation of immunocomplexes, are widely used as a
specific but insensitive indicator of immunoassay interference,
with such nonlinearity depending upon the affinity of the assay
antibodies relative to that of the insulin autoantibody if the
epitope is shared. Assay incubation time may affect results if
there is insufficient time for equilibrium to be re-established
between the immunoassay reagents and the putative hormone:
immunoglobulin complex. In our study, concordance among a
panel of widely used commercial assays was considerably
reduced in the presence of insulin autoantibodies, highlighting
a method-dependent sensitivity to this type of interference.
However, all of the assays used did show nonlinearity
(increased insulin recovery) with dilution. These observations
confirm the value of dilution studies in this context, but the
measurement is indirect, and the sensitivity of this method
remains unproven.
Immunoprecipitation with PEG is another common screening
tool for insulin–antibody complexes; however, this technique is
also assay dependent. We found PEG precipitation of plasma
from a patient with insulin autoantibodies demonstrated
decreased insulin recovery in PEG supernatant using all assays
except the Immulite 2000, which may relate to a matrix effect
caused by the viscosity of PEG in this assay. PEG precipitation
is known also to be susceptible to sample-specific matrix
effects,12 to exhibit differential precipitation of some
immunoglobulin subclasses, notably IgA,22 and is dependent on
the ability to measure insulin accurately if the original plasma
insulin concentration is low. It follows that, if the limitations of
this technique are considered, PEG precipitation can be used as
a simple practical method to screen for the presence of insulin–
antibody complexes in plasma.
We have now developed a GFC method coupled to ex vivo
insulin binding/exchange to refine identification of anti-insulin
autoantibodies capable of aggregating insulin reversibly without
recourse to radiolabelled materials. As expected, macroinsulin
was easily detectable by GFC in a patient with very high mea-
sured plasma insulin levels and multiple lines of biochemical
and clinical evidence supported the autoantibodies to be clini-
cally significant. The sensitivity of GFC is limited in some cases,
however, by low-input insulin concentration, for example when
blood is drawn after a prolonged fast, and potentially also by
the dissociation of insulin from weakly bound complexes during
sample dilution during the filtration process. Using a sample
from a patient with relatively low insulin concentration, ex vivo
incubation with a high concentration of free insulin increased
sensitivity of the GFC method by pushing the binding equilib-
rium in favour of insulin binding, permitting unequivocal
demonstration of the ability of the plasma to immunocomplex
insulin. We note also that this approach has potential utility also
in cases of sera stored at room temperature, where insulin may
have been degraded but where anti-insulin antibodies persist.
Demonstration of insulin exchange had additional value to
refute the presence of heterophile antibodies as the explanation
for the high molecular weight peak of insulin immunoreactivity.
Increased sensitivity of the GFC technique also enhances the
negative predictive value of the test, as in the second patient we
describe, in whom advanced liver disease offered an alternative
explanation for fasting hypoglycaemia, rather than insulin
sequestration by an insulin autoantibody.
In a development of this approach, we report that ex vivo use
of analogue insulins and analogue-specific insulin assays in elu-
ates further increases the clinical utility. Using these to demon-
strate the ability of analogue insulin to exchange with native
insulin binding to immunocomplexes, as in the third patient
described, who had an extremely high macroinsulin detected on
GFC, effectively ruled out heterophilic antibodies as the explana-
tion for abnormal immunoassay results and the high molecular
weight immunoreactivity fraction on GFC. This method is con-
siderably more convenient than exchange studies using radiola-
belled insulin.23
It is well understood that many immunoassay-detected anti-
insulin antibodies are of little or no clinical significance,24 and
so, there is a pressing need to develop robust laboratory
approaches to stratify such antibodies and to identify those likely
to perturb insulin pharmacokinetics and pharmacodynamics. We
here extend previous reports of the use of dilution studies, PEG
precipitation and GFC to delineate the strengths and limitations
of the approaches in the context of widely used commercial
immunoassays. While each approach has utility in the laboratory
investigation of anti-insulin autoantibodies, full understanding
of the performance of these approaches, and development of
efficient diagnostic algorithms, will require their application to a
larger population of patients with dysglycaemia and detectable
anti-insulin antibodies.
© 2016 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
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